These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 17561350)
1. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Estévez LG; Muñoz M; Alvarez I; Fernández Y; García-Mata J; Ruiz-Borrego M; Tusquets I; Seguí MA; Rodríguez-Lescure A; Adrover E; Lluch A Cancer Treat Rev; 2007 Aug; 33(5):474-83. PubMed ID: 17561350 [TBL] [Abstract][Full Text] [Related]
2. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment. Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608 [TBL] [Abstract][Full Text] [Related]
3. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?]. Herceg D; Vrbanec D Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533 [TBL] [Abstract][Full Text] [Related]
4. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions. Tang SC Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486 [TBL] [Abstract][Full Text] [Related]
5. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049 [TBL] [Abstract][Full Text] [Related]
6. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072 [TBL] [Abstract][Full Text] [Related]
7. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Sparano JA Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388 [TBL] [Abstract][Full Text] [Related]
8. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Moreno-Aspitia A; Perez EA Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124 [TBL] [Abstract][Full Text] [Related]
9. Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Martin M; Mackey J; Vogel C Breast; 2007 Dec; 16 Suppl 2():S127-31. PubMed ID: 17923408 [TBL] [Abstract][Full Text] [Related]
10. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Pal SK; Childs BH; Pegram M Breast Cancer Res Treat; 2010 Jan; 119(1):25-32. PubMed ID: 19795206 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant taxanes: more to the story. Gajria D; Seidman A; Dang C Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S41-9. PubMed ID: 20805064 [TBL] [Abstract][Full Text] [Related]
12. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cuppone F; Bria E; Carlini P; Milella M; Felici A; Sperduti I; Nisticò C; Terzoli E; Cognetti F; Giannarelli D Cancer; 2008 Jul; 113(2):238-46. PubMed ID: 18470908 [TBL] [Abstract][Full Text] [Related]
14. Advances in adjuvant chemotherapy for breast cancer: the role of taxanes. Kaklamani VG; Gradishar WJ J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S107-18. PubMed ID: 19795584 [TBL] [Abstract][Full Text] [Related]
15. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg. Hudis C Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262 [TBL] [Abstract][Full Text] [Related]
17. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. Shao N; Wang S; Yao C; Xu X; Zhang Y; Zhang Y; Lin Y Breast; 2012 Jun; 21(3):389-93. PubMed ID: 22542064 [TBL] [Abstract][Full Text] [Related]
18. First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment. Morabito A; Piccirillo MC; Monaco K; Pacilio C; Nuzzo F; Chiodini P; Gallo C; de Matteis A; Perrone F; Oncologist; 2007 Nov; 12(11):1288-98. PubMed ID: 18055848 [TBL] [Abstract][Full Text] [Related]
19. Taxanes in the adjuvant treatment of node-negative breast cancer patients. Ozdemir N; Aksoy S; Zengin N; Altundag K J BUON; 2012; 17(1):27-32. PubMed ID: 22517689 [TBL] [Abstract][Full Text] [Related]
20. Taxanes in the treatment of early breast cancer. Ring AE; Ellis PA Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]